Arix Bioscience, a global healthcare and life science company supporting medical innovation, has planned changes to its executive team to prepare for its next phase of growth and development.
Dr Joe Anderson, who has served as CEO of Arix since its inception in 2016, will transition to Chief Investment Officer to focus on new investments and work with existing group companies to build and realise value.
Anderson will continue to chair the investment committee, but will step down from the board of Arix. Executive chairman of Arix, Jonathan Peacock, will assume corporate and operating responsibilities and, working closely with the board of Arix, will lead the process of recruiting a CEO.
Since 2016 Joe Anderson has partnered with Jonathan Peacock and Sir Chris Evans to build the company and lead Arix through its IPO and recent fundraising.
Jonathan Peacock, Chairman of Arix, commented: “Arix has come a long way since its formation in 2016 and Joe’s experience as a venture capital investor has played an important role in our success. On behalf of the board, I would like to thank Joe for his contributions as CEO in building the company and I look forward to working with him as Arix embarks on its next stage of growth and development.”
Dr Joe Anderson, Chief Investment Officer of Arix, commented: “From the inception of Arix, the goal was to build a listed life-sciences group investing in and supporting innovative young companies. The build stage of Arix has substantively been completed, and now offers access to a growing portfolio of highly innovative, fast-developing life-science companies, hitherto largely only available to private equity investors. Arix’s core business is in good shape and strongly positioned to deliver growth."
"As Arix develops a strategy for its next phase of growth, it is appropriate to develop the leadership structure. I look forward to focusing more on investment, company building and helping to drive continued value creation.”
